NCT05923177View on ClinicalTrials.gov

Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Primary Breast Cancer
Interventions
DRUG

SPECT

One single injection of \[123I\] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.

Trial Locations (1)

Unknown

TomskNRMC, Tomsk

All Listed Sponsors
lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT05923177 - Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 | Biotech Hunter | Biotech Hunter